bioMérieux’s Future-Proof Portfolio of Diagnostic Solutions and Services Ensure End-to-End Compliance with Changing Cronobacter Regulations and Calls-To-Action

Formula Manufacturers and Suppliers Can Now Predict and Prevent Cronobacter Contamination via Comprehensive Risk-Profiles and Actionable Insights

CHICAGO – September 6, 2023 – In recognition of National Food Safety Education Month, bioMérieux, a world leader in in vitro diagnostics, continues its long-standing collaboration with the food safety industry to provide a comprehensive suite of solutions and services for infant formula manufacturers and ingredient suppliers to minimize risk of Cronobacter spp, Salmonella and other microbiological hazards at every stage of the production process. 

Anchored by GENE-UP^® Cronobacter, bioMérieux’s solutions ensure compliance with the U.S. Food and Drug Administration (FDA) call-to-action for the entirety of the infant formula supply chain to minimize the risk of Cronobacter sakazakii, as well as the recent U.S. Centers for Disease Control (CDC) announcement to add Cronobacter to its list of reportable diseases. 

In addition to GENE-UP^® Cronobacter, bioMérieux brings advanced genomic approaches and whole genome sequencing capabilities to enable partners to truly understand the microbiome of their entire production facility. bioMérieux is equipping manufacturers to detect, monitor, and investigate risks associated with C. sakazakii, Salmonella, and other microbiological hazards resulting in actionable insights to drive mitigation plans.

“The formula industry is taking the critical, necessary steps to enhance the quality control process to minimize the risk of Cronobacter and ensure the safety of our most vulnerable population,” said Miguel Villa, Senior Vice President, Industrial Microbiology - Americas, at bioMérieux. “As a longtime collaborator of the food safety industry, we’re proud to offer formula manufacturers and ingredient suppliers with best-in-class, quality control solutions that deliver actionable insights to increase operational efficiencies, regain public trust and further public health worldwide.”

September is National Food Safety Education Month - a concentrated effort by the industry and advocacy organizations to promote safe food handling and prevent foodborne illnesses. For more than 60 years, bioMérieux has been a leader in developing diagnostic solutions, working alongside food safety leaders to design and execute best-in-class environmental monitoring protocols. 

With the CDC reportable decision taking effect in 2024 and the recent FDA call-to-action regarding Cronobacter best practices, bioMérieux’s portfolio of solutions and services offers total compliance with the fast-changing regulatory landscape, including:

• GENE-UP^® Cronobacter: Real-time PCR (Polymerase Chain Reaction) for detection in both human food products and environmental production samples
• TEMPO^® EB: The first automated test for Enterobacteriaceae enumeration in food products in 24 hours including confirmation
• GENE-UP^® Salmonella: Real-time PCR solution for pathogen detection
• EnviroMap^®: Data-driven Environmental Monitoring (EM) program that helps to identify potential spoilage or safety issues in facilities to minimize risk of costly product recalls

Now available for implementation, the Cronobacter product portfolio empowers those working in the infant formula industry to stay one step ahead of changing regulations to ensure compliance and minimize contamination risk. 

For more information on bioMérieux’s end-to-end suite of solutions and services available for infant formula manufacturers and suppliers of ingredients, please visit www.biomerieux.com.

Pioneering Diagnostics

A world leader in the field of in vitro diagnostics since 1963, bioMérieux is present in 45 countries and serves more than 160 countries with the support of a large network of distributors. In 2022, revenues reached €3.6 billion, with over 90% of sales outside of France.

bioMérieux provides diagnostic solutions (systems, reagents, software and services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products. www.biomerieux.com

bioMérieux is listed on the Euronext Paris stock market. 

Symbol: BIM – ISIN Code: FR0013280286

Reuters: BIOX.PA/Bloomberg: BIM.FP